REDUCTION OF THE EFFLUENT VOLUME IN HIGH-OUTPUT ILEOSTOMY PATIENTS BY A SOMATOSTATIN ANALOG, SMS 201-995

被引：22
作者：
KUSUHARA, K [1 ]
KUSUNOKI, M [1 ]
OKAMOTO, T [1 ]
SAKANOUE, Y [1 ]
UTSUNOMIYA, J [1 ]
机构：
[1] HYOGO MED UNIV,DEPT SURG 2,1-1 MUKOGAWA CHO,NISHINOMIYA,HYOGO 663,JAPAN
来源：
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE | 1992年 / 7卷 / 04期
关键词：
D O I：
10.1007/BF00341221
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Twelve ileostomy patients were given subcutaneous SMS 201-995 therapy (100 mug t.d.s. for 5 days) in a randomized placebo-controlled trial. All patients had ileostomies constructed 60 cm proximal to the terminal ileum (proximal ileostomy) following restorative proctocolectomy. SMS 201-995 reduced the daily ileostomy output from 997 +/- 52 g to 736 +/- 28 g, P < 0.05, along with a decrease in daily sodium and chloride excretion (sodium: 92.60 +/- 8.51 to 75.22 +/- 8.64 mEq, chloride: 143.46 +/- 8.54 to 113.60 +/- 15.84 mEq; both P < 0.05). There were no significant changes in the plasma levels of glucagon, C peptide, insulin, renin or aldosterone with SMS 201-995 therapy. Patients developed no severe side effects and reported easier management of the ileostomy and a reduction in thirst. Our results suggest a possible clinical role for SMS 201-995 in the management of proximal ileostomy.
引用
收藏
页码：202 / 205
页数：4
相关论文
共 28 条
  • [1] Brazeau P., Vale W., Burbus R., Ling N., Rivier J., Guillemin R., Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone, Science, 179, pp. 77-79, (1973)
  • [2] Shally A.V., Dupont A., Arimura A., Redding T.W., Nishi N., Linthicum G.L., Schlesinger D.H., Isolation and structure of somatostatin from porcine hypothalami, Biochemistry, 15, pp. 509-514, (1976)
  • [3] Vale W., Brazeau P., Rivier C., Brown M., Bross B., Rivier J., Burgus R., Ling N., Guillemein R., Somatostatin, Recent Prog Horm Res, 31, pp. 365-397, (1975)
  • [4] Brownstein M., Arimura A., Sato H., Schally A.V., Kizer J.S., The regional distribution of somatostatin in the rat brain, Endocrinology, 96, pp. 1456-1461, (1975)
  • [5] Arimura A., Sato H., Dupont A., Nishi N., Schally A.V., Somatostatin: abundance of immunoreactive hormone in rat stomach and pancreas, Science, 189, pp. 1007-1009, (1975)
  • [6] Hall R., Snow M., Scanlon M., Mora B., Gomez-Pan A., Pituitary effects of somatostatin, Metabolism, 27, pp. 1257-1262, (1978)
  • [7] Reichlin S., Somatostatin, N Engl J Med, 309, pp. 1495-1501, (1983)
  • [8] Bloom S.R., Mortimer C.H., Thorner M.O., Besser G.M., Hall R., Gomez-Pan A., Roy V.M., Russel R.C.G., Coy D.H., Kastin A.J., Schally A.V., Inhibition of gastrin and gastric acid secretion by growth hormone release-inhibiting hormone, Lancet, 2, pp. 1106-1109, (1974)
  • [9] Boden G., Sivitz M.C., Owen O.E., Essa-Koumar N., Landor J.H., Somatostatin suppresses secretion and pancreatic exocrine secretion, Science, 190, pp. 163-165, (1975)
  • [10] Bloom S.R., Polak J.M., Glucagonomas, VIPomas and somatostatinomas, Clin Endocrinol Metab, 9, pp. 285-297, (1980)
123